1. Genotype-specific combinatorial drug sensitivities in melanoma.
Genotype-specific combinatorial drug sensitivities in melanoma. A, unsupervised clustering of maximum growth inhibition achieved out of the 9 concentration combinations tested for each cell line (columns) for each unique drug pair (rows). Partitioning of mutant BRAF cultures (Cluster 1) and mutant RAS or WT melanoma cultures (Cluster 2) is readily apparent. B, frequency of agents that in pairwise combinations elicit a GI25 or higher effect level and 15% or more growth inhibition in the mutant BRAF group relative to the other 2 groups. C, as in B but for mutant RAS melanomas.
Matthew A. Held et al. Cancer Discovery 2013;3:52-67
©2013 by American Association for Cancer Research